The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Merck Foundation ( the philanthropic arm of Merck KGaA Germany, conducted the 12th Edition of their annual conference, “Merck ...

In this article, we’ll break down the best health care stocks to watch or invest in right now, why the sector matters and how ...

In the latest trading session, Merck (MRK) closed at $111.11, marking a +1.52% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.16%. Elsewhere, the ...

Merck Foundation ( the philanthropic arm of Merck KGaA, Germany, in partnership with African and Asian First Ladies, released ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths ...

Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that abemaciclib, an oral cancer drug ...

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one ...